Went public 8/3/2000 at $14 per share
Filing Range: 7.2 mil. shares @ $10 to $12
Shares Outstanding: 30. mil. shares
Underwriters: Lehman Brothers/Lazard Freres & Co. LLC/ Prudential
Vector Healthcare/Fidelity Capital Markets
Company Counsel: Venture Law Group
Manager Counsel: Mintz Levin Cohn Ferris Glovsky & Popeo
Auditor: PricewaterhouseCoopers LLP
Develops biochip technology for the analysis of pharmacological data to predict the effects of promising drugs to fight cancer and immunological diseases.
Vulcan Ventures Inc.
Olympic Venture Partners
Pequot Capital Management Inc.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 04/01/1997 4 Early Stage 17500.1
2 04/01/1999 2 Later Stage 7600.0
3 03/14/2000 4 Later Stage 41581.0
(Data in $ millions)
Total Revenues: $1.0
Net Income: -19.8